Beginnings of Personalized Medicine for Myeloma

Ajai Chari, MD

Video Categories: Personalized Medicine

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
December 3, 2013

The Role of Hedgehog Pathway Inhibition in Advanced Basal Cell Carcinoma

In the first WCMC clinical commentary entitled, The Role of Hedgehog Pathway Inhibition in Advanced Basal Cell Carcinoma, Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD; Aleksander Sekulic, MD, PhD discuss how the hedgehog pathway plays a critical role in developing basal cell carcinoma and how inhibitors are providing new strategies [ Read More ]

March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.